Skip to main content
OpenTrials

Clinical trial condition

Diabetes Mellitus, Type 2

Explore clinical trials studying Diabetes Mellitus, Type 2. Study availability and eligibility vary by location and protocol.

7,977 public trials 716 recruiting studies
Refine in advanced search Browse all conditions

Diabetes Mellitus, Type 2 trial results

Completed

Efficacy and Safety of Linagliptin in Elderly Patients With Type 2 Diabetes

NCT01084005

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.63.61005 Boehringer Ingelheim Investigational Site Gosford, New South Wales, Australia
  • 1218.63.61006 Boehringer Ingelheim Investigational Site Herston, Queensland, Australia
  • 1218.63.61003 Boehringer Ingelheim Investigational Site Adelaide, South Australia, Australia
  • 1218.63.61002 Boehringer Ingelheim Investigational Site Daw Park, South Australia, Australia
View all 34 locations
View Trial Details
Completed

Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study

NCT01194830

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.75.059 Boehringer Ingelheim Investigational Site Birmingham, Alabama, United States
  • 1218.75.054 Boehringer Ingelheim Investigational Site Huntsville, Alabama, United States
  • 1218.75.035 Boehringer Ingelheim Investigational Site Mobile, Alabama, United States
  • 1218.75.101 Boehringer Ingelheim Investigational Site Toney, Alabama, United States
View all 93 locations
View Trial Details
Completed

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

NCT00601250

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.17.10003 Boehringer Ingelheim Investigational Site Chula Vista, California, United States
  • 1218.17.10014 Boehringer Ingelheim Investigational Site Spring Valley, California, United States
  • 1218.17.10001 Boehringer Ingelheim Investigational Site Walnut Creek, California, United States
  • 1218.17.10021 Boehringer Ingelheim Investigational Site Northglenn, Colorado, United States
View all 82 locations
View Trial Details
Completed

Safety and Efficacy of Linagliptin (BI 1356) Plus Metformin in Type 2 Diabetes, Factorial Design

NCT00798161

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.46.11005 Boehringer Ingelheim Investigational Site Calgary, Alberta, Canada
  • 1218.46.11003 Boehringer Ingelheim Investigational Site Edmonton, Alberta, Canada
  • 1218.46.11002 Boehringer Ingelheim Investigational Site Red Deer, Alberta, Canada
  • 1218.46.11006 Boehringer Ingelheim Investigational Site Vancouver, British Columbia, Canada
View all 138 locations
View Trial Details
Completed

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

NCT00299871

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +4 more
Locations
  • Sanofi-Aventis Administrative Office Bridgewater, New Jersey, United States
  • Sanofi-Aventis Administrative Office São Paulo, Brazil
  • Sanofi-Aventis Administrative Office Laval, Canada
  • Sanofi-Aventis Administrative Office Warsaw, Poland
View Trial Details
Completed

Japanese P III vs Voglibose and Placebo

NCT00654381

Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 2, Endocrine System Diseases, +3 more
Locations
  • 1218.23.05 Boehringer Ingelheim Investigational Site Asahi, Chiba, Japan
  • 1218.23.06 Boehringer Ingelheim Investigational Site Funabashi, Chiba, Japan
  • 1218.23.21 Boehringer Ingelheim Investigational Site Hitachinaka, Ibaraki, Japan
  • 1218.23.44 Boehringer Ingelheim Investigational Site Hitachiota, Ibaraki, Japan
View all 47 locations
View Trial Details

Related conditions